![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CEBPA |
Gene summary for CEBPA |
![]() |
Gene information | Species | Human | Gene symbol | CEBPA | Gene ID | 1050 |
Gene name | CCAAT enhancer binding protein alpha | |
Gene Alias | C/EBP-alpha | |
Cytomap | 19q13.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P49715 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1050 | CEBPA | LZE4T | Human | Esophagus | ESCC | 1.37e-02 | 5.32e-02 | 0.0811 |
1050 | CEBPA | LZE24T | Human | Esophagus | ESCC | 2.83e-07 | 9.25e-02 | 0.0596 |
1050 | CEBPA | LZE21T | Human | Esophagus | ESCC | 1.94e-03 | 1.47e-01 | 0.0655 |
1050 | CEBPA | P1T-E | Human | Esophagus | ESCC | 3.11e-06 | 5.20e-01 | 0.0875 |
1050 | CEBPA | P2T-E | Human | Esophagus | ESCC | 2.41e-14 | 2.09e-01 | 0.1177 |
1050 | CEBPA | P4T-E | Human | Esophagus | ESCC | 9.29e-07 | 1.48e-01 | 0.1323 |
1050 | CEBPA | P5T-E | Human | Esophagus | ESCC | 4.62e-02 | 3.08e-02 | 0.1327 |
1050 | CEBPA | P8T-E | Human | Esophagus | ESCC | 4.63e-16 | 1.82e-01 | 0.0889 |
1050 | CEBPA | P9T-E | Human | Esophagus | ESCC | 1.92e-13 | 3.61e-01 | 0.1131 |
1050 | CEBPA | P10T-E | Human | Esophagus | ESCC | 2.90e-19 | 3.66e-01 | 0.116 |
1050 | CEBPA | P11T-E | Human | Esophagus | ESCC | 1.82e-09 | 2.16e-01 | 0.1426 |
1050 | CEBPA | P12T-E | Human | Esophagus | ESCC | 1.58e-17 | 3.30e-01 | 0.1122 |
1050 | CEBPA | P15T-E | Human | Esophagus | ESCC | 4.95e-21 | 5.47e-01 | 0.1149 |
1050 | CEBPA | P16T-E | Human | Esophagus | ESCC | 4.76e-04 | 5.12e-02 | 0.1153 |
1050 | CEBPA | P20T-E | Human | Esophagus | ESCC | 6.65e-08 | 1.23e-01 | 0.1124 |
1050 | CEBPA | P22T-E | Human | Esophagus | ESCC | 1.12e-18 | 2.37e-01 | 0.1236 |
1050 | CEBPA | P23T-E | Human | Esophagus | ESCC | 9.10e-14 | 2.34e-01 | 0.108 |
1050 | CEBPA | P26T-E | Human | Esophagus | ESCC | 2.70e-14 | 1.38e-01 | 0.1276 |
1050 | CEBPA | P27T-E | Human | Esophagus | ESCC | 2.04e-02 | 7.49e-02 | 0.1055 |
1050 | CEBPA | P28T-E | Human | Esophagus | ESCC | 2.84e-12 | 2.53e-01 | 0.1149 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00712487 | Liver | Cirrhotic | cellular response to metal ion | 73/4634 | 197/18723 | 7.73e-05 | 8.54e-04 | 73 |
GO:00712417 | Liver | Cirrhotic | cellular response to inorganic substance | 81/4634 | 226/18723 | 1.21e-04 | 1.20e-03 | 81 |
GO:00346126 | Liver | Cirrhotic | response to tumor necrosis factor | 89/4634 | 253/18723 | 1.24e-04 | 1.22e-03 | 89 |
GO:005134812 | Liver | Cirrhotic | negative regulation of transferase activity | 93/4634 | 268/18723 | 1.55e-04 | 1.47e-03 | 93 |
GO:00303242 | Liver | Cirrhotic | lung development | 65/4634 | 177/18723 | 2.49e-04 | 2.25e-03 | 65 |
GO:00303232 | Liver | Cirrhotic | respiratory tube development | 66/4634 | 181/18723 | 2.82e-04 | 2.49e-03 | 66 |
GO:00016495 | Liver | Cirrhotic | osteoblast differentiation | 80/4634 | 229/18723 | 3.39e-04 | 2.91e-03 | 80 |
GO:00713566 | Liver | Cirrhotic | cellular response to tumor necrosis factor | 79/4634 | 229/18723 | 5.68e-04 | 4.45e-03 | 79 |
GO:00018925 | Liver | Cirrhotic | embryonic placenta development | 34/4634 | 82/18723 | 6.36e-04 | 4.85e-03 | 34 |
GO:004259312 | Liver | Cirrhotic | glucose homeostasis | 86/4634 | 258/18723 | 1.12e-03 | 7.73e-03 | 86 |
GO:003350012 | Liver | Cirrhotic | carbohydrate homeostasis | 86/4634 | 259/18723 | 1.28e-03 | 8.61e-03 | 86 |
GO:00015035 | Liver | Cirrhotic | ossification | 127/4634 | 408/18723 | 1.89e-03 | 1.19e-02 | 127 |
GO:00614585 | Liver | Cirrhotic | reproductive system development | 132/4634 | 427/18723 | 2.07e-03 | 1.28e-02 | 132 |
GO:00486085 | Liver | Cirrhotic | reproductive structure development | 131/4634 | 424/18723 | 2.19e-03 | 1.34e-02 | 131 |
GO:00025735 | Liver | Cirrhotic | myeloid leukocyte differentiation | 70/4634 | 208/18723 | 2.34e-03 | 1.42e-02 | 70 |
GO:00196271 | Liver | Cirrhotic | urea metabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:00719411 | Liver | Cirrhotic | nitrogen cycle metabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:003367312 | Liver | Cirrhotic | negative regulation of kinase activity | 78/4634 | 237/18723 | 2.73e-03 | 1.59e-02 | 78 |
GO:00321032 | Liver | Cirrhotic | positive regulation of response to external stimulus | 131/4634 | 427/18723 | 2.90e-03 | 1.66e-02 | 131 |
GO:00605411 | Liver | Cirrhotic | respiratory system development | 67/4634 | 203/18723 | 4.81e-03 | 2.52e-02 | 67 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa052215 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0493222 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0493232 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0493242 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa05221 | Liver | HCC | Acute myeloid leukemia | 41/4020 | 67/8465 | 1.64e-02 | 3.90e-02 | 2.17e-02 | 41 |
hsa0493252 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa052211 | Liver | HCC | Acute myeloid leukemia | 41/4020 | 67/8465 | 1.64e-02 | 3.90e-02 | 2.17e-02 | 41 |
hsa0493228 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa052214 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
hsa04932112 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa0522112 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEBPA | SNV | Missense_Mutation | rs780335632 | c.803N>T | p.Gly268Val | p.G268V | P49715 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CEBPA | SNV | Missense_Mutation | c.840N>C | p.Lys280Asn | p.K280N | P49715 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
CEBPA | SNV | Missense_Mutation | c.1015C>T | p.Arg339Trp | p.R339W | P49715 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CEBPA | SNV | Missense_Mutation | c.947A>C | p.Glu316Ala | p.E316A | P49715 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CEBPA | SNV | Missense_Mutation | novel | c.955A>G | p.Ser319Gly | p.S319G | P49715 | protein_coding | tolerated(0.05) | benign(0.171) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CEBPA | SNV | Missense_Mutation | c.1073N>T | p.Ala358Val | p.A358V | P49715 | protein_coding | deleterious(0.01) | possibly_damaging(0.788) | TCGA-EC-A1QX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD | |
CEBPA | SNV | Missense_Mutation | c.866N>A | p.Arg289His | p.R289H | P49715 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VQ-A8PP-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD | |
CEBPA | SNV | Missense_Mutation | novel | c.869N>T | p.Glu290Val | p.E290V | P49715 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1050 | CEBPA | TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | OICR-9429 | 26167872 | ||
1050 | CEBPA | TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | N/A | 20038735,26601784,19171880,22814295,25241285,23521373 |
Page: 1 |